CDK6 is an inclusion criterion in 11 clinical trials for malignant solid tumor, of which 10 are open and 1 is closed. Of the trials that contain CDK6 status and malignant solid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 10 are phase 2 (9 open) [4].

CDK6 is an inclusion criterion in 6 clinical trials for medulloblastoma, of which 6 are open and 0 are closed. Of the trials that contain CDK6 status and medulloblastoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (2 open), and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 4 clinical trials for malignant glioma, of which 4 are open and 0 are closed. Of the trials that contain CDK6 status and malignant glioma as inclusion criteria, 3 are early phase 1 (3 open) and 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 4 clinical trials for medulloblastoma, non-WNT/non-SHH, of which 4 are open and 0 are closed. Of the trials that contain CDK6 status and medulloblastoma, non-WNT/non-SHH as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (1 open), and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 3 clinical trials for breast carcinoma, of which 1 is open and 2 are closed. Of the trials that contain CDK6 status and breast carcinoma as inclusion criteria, 3 are phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for central nervous system embryonal neoplasm, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and central nervous system embryonal neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for central nervous system ganglioneuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and central nervous system ganglioneuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for central nervous system neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and central nervous system neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for colorectal carcinoma, of which 1 is open and 1 is closed. Of the trials that contain CDK6 status and colorectal carcinoma as inclusion criteria, 2 are phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for desmoplastic/nodular medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and desmoplastic/nodular medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for glioblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and glioblastoma as inclusion criteria, 1 is early phase 1 (1 open) and 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and head and neck squamous cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for large cell/anaplastic medulloblastoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and large cell/anaplastic medulloblastoma as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for medulloblastoma with extensive nodularity, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and medulloblastoma with extensive nodularity as inclusion criteria, 1 is phase 2 (1 open) and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for medulloblastoma, SHH-activated, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and medulloblastoma, SHH-activated as inclusion criteria, 2 are phase 1 (2 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for medulloblastoma, WNT-activated, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and medulloblastoma, WNT-activated as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for medulloepithelioma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and medulloepithelioma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for melanoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and melanoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for non-hodgkin lymphoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and non-hodgkin lymphoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and ovarian carcinoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK6 is an inclusion criterion in 2 clinical trials for soft tissue sarcoma, of which 2 are open and 0 are closed. Of the trials that contain CDK6 status and soft tissue sarcoma as inclusion criteria, 2 are phase 2 (2 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for adenocarcinoma of the gastroesophageal junction, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, IDH-mutant, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and anaplastic astrocytoma, IDH-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for anaplastic ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and anaplastic ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and anaplastic oligodendroglioma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and anaplastic oligodendroglioma, IDH-mutant and 1p/19q-codeleted as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for anaplastic pleomorphic xanthoastrocytoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and anaplastic pleomorphic xanthoastrocytoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for atypical teratoid/rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and atypical teratoid/rhabdoid tumor as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for bile duct carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and bile duct carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and bladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains CDK6 status and cancer as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for cervical carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and cervical carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for chordoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and chordoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for dedifferentiated chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and dedifferentiated chondrosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for diffuse glioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and diffuse glioma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for diffuse midline glioma, H3 K27M-mutant, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and diffuse midline glioma, H3 K27M-mutant as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, C19MC-altered, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and embryonal tumor with multilayered rosettes, C19MC-altered as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for embryonal tumor with multilayered rosettes, not otherwise specified, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and embryonal tumor with multilayered rosettes, not otherwise specified as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for endometrial endometrioid adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and endometrial endometrioid adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for ependymoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and ependymoma as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for ependymoma, RELA fusion-positive, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and ependymoma, RELA fusion-positive as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for esophageal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK6 status and esophageal carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for fallopian tube carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and fallopian tube carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and gastric adenocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK6 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 0 are open and 1 is closed. Of the trial that contains CDK6 status and germ cell tumor as inclusion criteria, 1 is phase 2 (0 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and head and neck carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for high-grade glioma, NOS, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and high-grade glioma, NOS as inclusion criteria, 1 is phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for meningioma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and meningioma as inclusion criteria, 1 is early phase 1 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for mucosal melanoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and mucosal melanoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for non-small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and non-small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and osteosarcoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and ovarian epithelial tumor as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for pancreatic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and pancreatic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for pineoblastoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and pineoblastoma as inclusion criteria, 1 is phase 4 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for primary peritoneal carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and primary peritoneal carcinoma as inclusion criteria, 1 is phase 2 (1 open) [4].

CDK6 is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and squamous cell lung carcinoma as inclusion criteria, 1 is no phase specified (1 open) [4].